Product Description
Malaria Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01026246)
Mechanisms of Action: GYPA Binder,Vaccine
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute of Allergy and Infectious Diseases (NIAID)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01026246 | P1 |
Completed |
Malaria, Falciparum |
2012-03-01 |
2019-03-19 |
Treatments |
|
| N01AI80002C | P1 |
Completed |
Malaria, Falciparum |
2008-04-01 |
2019-03-21 |
Treatments |